Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6152W HIGH $3.00
Volume
510.02 K
Value Traded
627.89 K
Short % Float
6.13%
Days to Cover
8.6
+9.82%Week
+24.49%1 Month
+79.51%3 Month
+33.41%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
131.30 M
EPS (TTM)
-1.58
P/E Ratio
-
Ent. Value
108.34 M
Total Shares
106.74 M
Float Shares
31.43 M
Insiders
70.56%
Institutions
22.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
DH Catalyst Timeline
Dated clinical, regulatory and corporate events for Definitive Healthcare Corp. Class A Common Stock
Past FDA Catalysts and PDUFA Decisions
How DH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Definitive Healthcare Corp. Class A is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coop KevinDirector, Officer (Chief Executive Officer) | Disposition | -37,593 4,975,229 held | $0.80 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.3 % | 3.96 M | 360.00 K |
Ownership Trends
DH Short Interest
Shares sold short, counted twice a month.
6.13%
Short % of Float
of tradable shares sold short
1.9M
Shares Sold Short
+15.0% vs prior count
8.6 High
Days to Cover
trading days of normal volume to buy every short share back
222.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DH ranks across every disease it competes in
Competitive Position is a premium feature
See how DH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDH News
-DH
Nov 4, 2026▲ +5.1%today
Definitive Healthcare announces executive appointments to bolster AI-powered initiatives across the company
Definitive Healthcare announced the appointment of Rebecca Marani as Chief Product Officer and Srinivas Attipalli as SVP, Head of AI and Data. These changes aim to strengthen the company's AI strategy as it prepares to launch a new AI-powered intelligence platform. The platform is expected to streamline data research and improve decision-making in healthcare.
Read more →-DH
Oct 1, 2026Definitive Healthcare Joins the Network Advertising Initiative to Strengthen Data Privacy Compliance in Healthcare Marketing
Definitive Healthcare has joined the Network Advertising Initiative (NAI) to enhance its commitment to data privacy in healthcare marketing. This membership reinforces the company's adherence to rigorous privacy standards and compliance with federal and state regulations. Executives emphasized the importance of protecting healthcare data while navigating complex advertising challenges.
Read more →-DH
Sep 2, 2026▲ +15.3%on this news
Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
Definitive Healthcare's Board of Directors announced receipt of a non-binding acquisition proposal from Advent International to buy all outstanding shares for $1.02 each. The Special Committee, composed of independent directors, will review the proposal with their advisors. No decisions have been made yet regarding the transaction.
Read more →-DH
Sep 2, 2026▲ +15.3%on this newsshared move
Definitive Healthcare Appoints Clay Ritchey as CEO
Definitive Healthcare appointed Clay Ritchey as CEO, effective September 8, 2026. He succeeds Kevin Coop, who left the role on August 31, 2026. Ritchey brings extensive healthcare experience and aims to drive growth and innovation, particularly with the upcoming AI-powered platform. His leadership is expected to enhance the company's market position.
Read more →-DH
Aug 10, 2026▼ -7.8%on this news
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Definitive Healthcare reported its Q2 2026 financial results, showing revenue of $55.2 million, a 9% decrease from the previous year. However, the company improved its net loss to $(7.5) million and launched Turbo, an AI-powered platform. The outlook for Q3 2026 anticipates revenue between $54.0 million and $55.0 million.
Read more →-DH
Aug 6, 2026Definitive Healthcare Launches Early Adopter Program for New AI-Powered Healthcare Intelligence Platform
Definitive Healthcare announced an early adopter program for its new AI-powered platform, set for general availability later in 2026. This platform integrates various healthcare data to help organizations identify growth opportunities and make informed decisions. Early adopters will provide feedback to refine the product before its official launch.
Read more →-DH
Aug 3, 2026Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. (Nasdaq: DH) will report second quarter 2026 financial results on August 10, 2026, after market close. The company hosts a conference call and webcast at 5:00 PM ET to discuss these results. Investors can access the live audio webcast via the Investor Relations website or dial-in numbers. A replay of the call remains available through September 9, 2026.
Read more →-DH
Jul 27, 2026Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare announced the grant of inducement awards to Srinivas Attipalli, its new SVP and Head of AI & Data - Product. The award consists of 1,063,830 time-based restricted stock units, effective July 24, 2026. These awards are part of the company's 2023 Inducement Plan and will vest over time, contingent on continued employment.
Read more →-DH
May 21, 2026Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights
Definitive Healthcare announced enhancements to its data platform, including expanded medical claims insights and a new HubSpot integration. The updates aim to provide organizations with a clearer view of the healthcare ecosystem and improve decision-making. New AI search capabilities and access to healthcare professional data in Salesforce are also part of the upgrades.
Read more →-DH
May 7, 2026Definitive Healthcare Reports Financial Results for First Quarter 2026 First Quarter Revenue at Top End of Guidance
Definitive Healthcare Corp. reported its financial results for Q1 2026, showing revenue of $55.9 million, a 6% decrease from Q1 2025. Despite a significant net loss influenced by goodwill impairment charges, the company's adjusted net income rose to $8.5 million from $7.0 million a year prior. CEO Kevin Coop expressed confidence in the company's strategic investments and noted improvements in retention rates. Looking ahead, the guidance for Q2 2026 anticipates revenue between $55.0 and $56.0 million.
Read more →-DH
Apr 23, 2026Definitive Healthcare Announces Timing of Its First Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. will announce its first quarter 2026 financial results on May 7, 2026, after market close. A conference call and webcast will follow at 5:00 PM ET. Investors can access the live event via the company's Investor Relations website and dial in for audio. A replay will be available until June 6, 2026.
Read more →-DH
Feb 26, 2026Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
Definitive Healthcare Corp. announced its financial results for Q4 and the full fiscal year 2025, reporting a revenue of $61.5 million for the fourth quarter, which marked a 1% decrease from the previous year. However, the company demonstrated significant improvement in net losses compared to Q4 2024, mainly due to a notable reduction in goodwill impairment charges. The overall revenue for the full fiscal year 2025 was reported at $241.5 million, down from $252.2 million in 2024. Despite these challenges, Definitive Healthcare expressed confidence in their strategies for retention and growth as they enter 2026, with optimistic forecasts for revenue and operating income.
Read more →-DH
Nov 6, 2025Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025 Third Quarter Revenue Delivered at High End of Guidance
Definitive Healthcare Corp. reported its financial results for the third quarter of fiscal year 2025, revealing revenue of $60.0 million, a 4% decrease from the previous year. However, the company highlighted that its income metrics, including adjusted EBITDA, surpassed expectations, indicating positive operational adjustments. New client acquisitions in the biopharma and medical device sectors contributed to optimistic growth potential. Looking ahead, the company has provided a financial guidance for the fourth quarter, fostering a cautious yet optimistic outlook on revenue.
Read more →-DH
Aug 7, 2025Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025 Second Quarter Revenue Exceeded Guidance
Definitive Healthcare reported its financial results for the second quarter of fiscal year 2025, highlighting revenues of $60.8 million, which fell short of last year’s figure but exceeded guidance. The company revealed a net loss reduced sharply from a previous significant loss, signaling operational improvements. Adjusted EBITDA was 31% of revenue, and cash flow from operations reached $9.3 million. Additionally, Definitive Healthcare announced an increase in its revenue guidance and outlook for adjusted EBITDA for the year ahead.
Read more →-DH
May 8, 2025Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025 First Quarter Revenue Exceeded Guidance
Definitive Healthcare Corp. reported its financial results for the first quarter of fiscal year 2025, indicating that though revenue exceeded initial guidance, it faced a 7% decline from the previous year. The company registered a significant net loss attributed largely to goodwill impairment charges. However, adjusted income metrics showed a degree of stability, with positive cash flow from operations and strong customer acquisition highlighted as strengths. The firm maintains a focus on operational efficiency and predicts future revenue growth despite ongoing economic uncertainties.
Read more →-DH
Feb 27, 2025Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024 Fourth quarter and full year 2024 revenue exceeded guidance
Definitive Healthcare Corp. reported its financial results for the fourth quarter and full fiscal year 2024, where revenue was $62.3 million, a decrease from the previous year. The company experienced a significant net loss of $(591.4) million for the full year, largely due to goodwill impairment charges. However, it achieved an adjusted net income of $55.1 million, and cash flow from operations rose to $58.2 million, reflecting growth. Looking ahead, the company has issued guidance predicting revenue in the range of $230.0 to $240.0 million for 2025.
Read more →-DH
Nov 7, 2024Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024 Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization Framingham, MA (
Definitive Healthcare reported financial results for the third quarter of fiscal year 2024, surpassing revenue guidance with $62.7 million. The company faced a net loss of $(187.8) million due to goodwill impairment but showed an increase in adjusted net income. Notable elements included the authorization of a $100 million stock repurchase program, growth in enterprise customers, and recent wins with major health organizations. Despite a decline in overall revenue and EBITDA, management expressed optimism about future prospects.
Read more →-DH
Aug 5, 2024Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024 Second quarter revenue grew 5% year-over-year to $63.7 million Framingham, MA (
Definitive Healthcare reported its financial results for the second quarter of fiscal year 2024, highlighting a 5% increase in revenue year-over-year, totaling $63.7 million. However, the company experienced a significant net loss of $(306.2) million, largely attributed to goodwill impairment charges. Adjusted net income showed some improvement, rising to $14.2 million, while adjusted EBITDA increased by 21% to $20.9 million. Additionally, the enterprise customer base grew 6% from the previous year, ending with 537 enterprise customers.
Read more →-DH
May 7, 2024Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024 First quarter revenue grew 7% year-over-year to $63.5 million Framingham, MA (
Definitive Healthcare Corp. reported a revenue increase of 7% year-over-year for Q1 2024, totaling $63.5 million. The company also noted improvements in adjusted net income and EBITDA margins, driven by operational efficiencies. Despite these positives, it reported a net loss, although less severe than the prior year. Additionally, the company anticipates modest revenue growth for the upcoming quarter, with a stock repurchase program approved to bolster shareholder value.
Read more →About Definitive Healthcare Corp. Class A Common Stock
Headquarters492 OLD CONNECTICUT PATH, SUITE 401, FRAMINGHAM, MA, 01701
BIOPHARMAWATCH ELITE PLUS
Trade the next DH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime